



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/17 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

1617

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$ 80.00)

Complete if Known

Application Number 09/770,901
Filing Date 01/26/01
First Named Inventor FAOUR, J. et al.
Examiner Name S. A. Jiang
Group Art Unit 1617
Attorney Docket No. PHUS-28

JAN 3 0 2002
CH CENTER 1600/2000

RECEIVED

METHOD OF PAYMENT

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number
Deposit Account Name

- Charge Any Additional Fee Required
Under 37 CFR 1.16 and 1.17
 Applicant claims small entity status.
See 37 CFR 1.27

2. Payment Enclosed:

Check Credit card Money Order Other

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee (\$)	Fee Code (\$)	Fee (\$)	Fee Description	Fee Paid
105	130	205	65		Surcharge - late filing fee or oath	
127	50	227	25		Surcharge - late provisional filing fee or cover sheet	
139	130	139	130		Non-English specification	
147	2,520	147	2,520		For filing a request for ex parte reexamination	
112	920*	112	920*		Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*		Requesting publication of SIR after Examiner action	
115	110	215	55		Extension for reply within first month	
116	390	216	195		Extension for reply within second month	
117	890	217	445		Extension for reply within third month	
118	1,390	218	695		Extension for reply within fourth month	
128	1,890	228	945		Extension for reply within fifth month	
119	310	219	155		Notice of Appeal	
120	310	220	155		Filing a brief in support of an appeal	
121	270	221	135		Request for oral hearing	
138	1,510	138	1,510		Petition to institute a public use proceeding	
140	110	240	55		Petition to revive - unavoidable	
141	1,240	241	620		Petition to revive - unintentional	
142	1,240	242	620		Utility issue fee (or reissue)	
143	440	243	220		Design issue fee	
144	600	244	300		Plant issue fee	
122	130	122	130		Petitions to the Commissioner	
123	50	123	50		Processing fee under 37 CFR 1.17(q)	
126	180	126	180		Submission of Information Disclosure Stmt	
581	40	581	40		Recording each patent assignment per property (times number of properties)	
146	710	246	355		Filing a submission after final rejection (37 CFR § 1.129(a))	
149	710	249	355		For each additional invention to be examined (37 CFR § 1.129(b))	
179	710	279	355		Request for Continued Examination (RCE)	
169	900	169	900		Request for expedited examination of a design application	
Other fee (specify) _____						
*Reduced by Basic Filing Fee Paid						SUBTOTAL (3) (\$ 0.00)

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
103	18	203
102	80	202
104	270	204
109	80	209
110	18	210
		9
Claims in excess of 20		
Independent claims in excess of 3		
Multiple dependent claim, if not paid		
** Reissue independent claims over original patent		
** Reissue claims in excess of 20 and over original patent		
SUBTOTAL (2) (\$ 80.00)		

*or number previously paid, if greater; For Reissues, see above

*Reduced by Basic Filing Fee Paid


SUBTOTAL (3) (\$ 0.00)

SUBMITTED BY

Name (Print/Type)	Rick Matos	Registration No. (Attorney/Agent)	40,082	Telephone	972-747-7373
Signature	12-20-01				

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Decket No. PHUS-28

JAN 24 2002

SC174
P A T E N T & T R A D E M A R K O F F I C E

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent application of:
FAOUR, J. et al.
Serial No.: 09/770,901
Filed: January 26, 2001

§
§
§
§

Group Art Unit: 1617
Examiner: Shaojia A. Jiang


For: Pharmaceutical compositions containing
A COX-II inhibitor and a muscle
relaxant

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on December 20, 2001.

Rick Matos
Typed or printed name of person mailing paper

Signature of person mailing paper

RECEIVED
JAN 30 2002
TECH CENTER 1600/PB
10/13
A. Harmon
2/4/02

AMENDMENT

In response to the Office Action mailed September 28, 2001, Applicants hereby submit the following response. Please amend the application as follows.

IN THE CLAIMS

7) (Amended) The pharmaceutical composition of claim 1, wherein the muscle relaxant is selected from the group consisting of alcuronium, alosetron, aminophylline, baclofen, carisoprodol [(SOMA®)], chlorphenesin, chlorphenesin carbamate, chlorzoxazone [(PARAFON FORTE®)], chlormezanone, cyclobenzaprine [(FLEXERIL®)], dantrolene, decamethonium, diazepam, dyphylline, eperisone, ethaverine, gallamine triethiodide, hexafluorenium, mephenesin, metaxalone [(SKELAXIN®)], methocarbamol [(ROBAXIN®)], metocurine iodide, orphenadrine [(NORFLEX®)], pancuronium, papaverine, pipecuronium, pridinol [(pridinolum)], succinylcholine, theophylline, tizanidine, tolperisone, tubocurarine, vecuronium, idrocilamide, ligustilide, cnidilide, and senkyunolide.

8) (Amended) The pharmaceutical composition of claim 1, wherein the COX-II inhibitor is selected from the group consisting of rofecoxib [(VIOXX™, MK-0966)], celecoxib [(CELEBREX™, SC-58635)], flosulide [(CGP-28238)], NS-398, DUP-697, meloxicam, 6-methoxy-2-naphthylacetic acid [(6-MNA)], nabumetone [(prodrug for 6-MNA)], etodolac, nimesulide, SC-5766, SC-58215, T-614, and combinations thereof.

02/04/2002 RHARMON 00000004 501527 09770901
01 FC:197

80.00
000000045 09770901

01/26/2002 RHARMON 000000045 09770901
01 FC:197